European Journal of Clinical Microbiology

, Volume 6, Issue 4, pp 479–481 | Cite as

In vivo and in vitro activity of roxithromycin againstToxoplasma gondii in mice

  • B. J. Luft
New Antimicrobial Agents


Roxithromycin protected mice against a lethal infection with the extremely virulent RH strain and the CS6 strain ofToxoplasma gondii. Therapy initiated 2 h after infection with 2×103 or 2×104 RH or C56 tachyzoites protected more than 80% of the mice, compared with 0% of untreated controls (p < 0.001). Paradoxically,Toxoplasma gondii was isolated more frequently (> 80%)in treated mice surviving infection with the less virulent strain (CS6) than those surviving infection with the more virulent RH strain (< 25%). Furthermore, in vitro studies revealed that roxithromycin at dosages up to 250 μg/ml had no effect on the proliferation ofToxoplasma gondii in murine peritoneal macrophage cultures.


Internal Medicine Untreated Control Virulent Strain Peritoneal Macrophage Treated Mouse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jones, R. N., Barry, A. L., Thornberry, C.: In vitro evaluation of three new macrolide antimicrobial agents, RU 128965, RU 29065, and RU 29702, and comparisons with other orally administered drugs. Antimicrobial Agents and Chemotherapy 1983, 24: 209–215.PubMedGoogle Scholar
  2. 2.
    Chan, J., Luft, B. J.: Activity of roxithromycin (RU 28965), a macrolide againstToxoplasma gondii in mice. Antimicrobial Agents and Chemotherapy 1986, 30: 323–324.PubMedGoogle Scholar
  3. 3.
    Eyles, D. E., Coleman, N.: Notes on the treatment of acute experimental toxoplasmosis of the mouse with chlortetracycline and tetracycline. Antibiotics and Chemotherapy 1955, 5: 529–539.Google Scholar
  4. 4.
    Chan, J., Siegel, J. P., Luft, B. J.: Demonstration of T-cell dysfunction during acute toxoplasma infection. Cellular Immunology 1986, 98: 422–432.PubMedGoogle Scholar
  5. 5.
    Araujo, F. G., Remington, J. S.: Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrobial Agents and Chemotherapy 1974, 5: 647–651.PubMedGoogle Scholar
  6. 6.
    Luft, B. J., Remington, J. S.: The adverse effect of pregnancy on macrophage activation. Cellular Immunology 1984, 85: 94–99.PubMedGoogle Scholar
  7. 7.
    Mack, D. G., McLeod, R.: New micromethod to study the effect of antimicrobial agents onToxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrobial Agents and Chemotherapy 1984, 26: 31–35.PubMedGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1987

Authors and Affiliations

  • B. J. Luft
    • 1
  1. 1.Division of Infectious Diseases, Health Sciences Center, T-15, 080State University of New York at Stony BrookNew YorkUSA

Personalised recommendations